NCT04992546View on ClinicalTrials.gov

Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

August 13, 2021

Primary Completion Date

December 28, 2022

Study Completion Date

December 28, 2022

Conditions
Atopic Dermatitis
Interventions
DRUG

PRN473 (SAR444727)

White to off-white gel suspension

DRUG

Placebo

White to off-white gel suspension

Trial Locations (12)

33172

Lenus Research & Medical Group-Site Number:8400006, Sweetwater

33173

Florida International Research Center-Site Number:8400017, Miami

33607

Clinical Research Trials of Florida, Inc-Site Number:8400013, Tampa

43215

Remington Davis Inc-Site Number:8400012, Columbus

77004

Center for Clinical Studies, LTD. LLP-Site Number:8400014, Houston

77802

J&S Studies-Site Number:8400015, Bryan

78213

Progressive Clinical Research-Site Number:8400002, San Antonio

90025

California Allergy & Asthma Medical Group-Site Number:8400008, Los Angeles

90806

Collaborative Neuroscience Research-Site Number:8400004, Long Beach

L8L 3C3

Investigational Site Number :1240008, Hamilton

N6H 5L5

Investigational Site Number :1240007, London

G1G 3Y8

Investigational Site Number :1240002, Québec

All Listed Sponsors
lead

Principia Biopharma, a Sanofi Company

INDUSTRY

NCT04992546 - Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis | Biotech Hunter | Biotech Hunter